New Chikungunya Vaccine Available: A Game-Changer for Alberta Travelers!

A revolutionary new vaccine, IXCHIQ, is now available to Albertan travelers, offering hope against the debilitating effects of chikungunya. This summer, Health Canada approved IXCHIQ as the world’s first licensed chikungunya vaccine, and Alberta pharmacies and travel clinics have begun administering it.

This vaccine could play a crucial role for the estimated seven million Canadians planning to travel to tropical destinations, where chikungunya is a growing concern. The virus, transmitted by the Aedes aegypti and Aedes albopictus mosquitoes, can lead to severe symptoms such as high fever, excruciating joint pain, muscle pain, fatigue, nausea, and rashes. For some, these symptoms can linger for years, drastically affecting quality of life.

Dr. Lynora Saxinger from the University of Alberta explains the impressive safety profile and the long-lasting immunity provided by IXCHIQ. She notes, "Chikungunya can result in severe joint pain and inflammatory arthritis, which is why many travelers are eager to secure vaccination." The vaccine has shown promising results, with a study published in The Lancet indicating a staggering 98.9% seroresponse rate within 28 days of vaccination.

While the vaccine offers substantial protection, experts warn of potential mini-outbreaks. If infected travelers return home and are bitten by local mosquitoes, there is a risk of the virus spreading. The WHO considers chikungunya a "growing public health threat," particularly as climate change facilitates the spread of its vector, the Aedes mosquito, which has been reported in regions as far north as southern Ontario.

Travelers should be aware of the symptoms, as evidenced by the experience of Bruce Wale from Victoria, B.C., who contracted chikungunya during a trip to Mexico. Initially mistaking his symptoms for COVID-19, he faced months of debilitating pain and discomfort after returning home. Wale's story highlights the importance of understanding the risks of mosquito-borne diseases during travel.

Chikungunya is endemic in many parts of the world, including China, India, South America, and Africa. With Canada being only the second country to approve IXCHIQ after the U.S., it stands as a significant development in travel medicine. As travelers prepare for winter getaways to warmer climates, health experts are urging them to consider getting vaccinated against chikungunya, ensuring they can enjoy their vacations without the shadow of debilitating illness hanging over them.

Stay informed and protect your health – the vaccine is just a visit away!